Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp or approximately 250 cm2 on the chest: a Phase III randomized controlled trial.
Ingenol mebutate (IngMeb) 0.015% or 0.05% is approved for actinic keratosis (AK) areas ≤25 cm2; some patients require treatment of larger fields. Determine efficacy and safety of IngMeb 0.027% in areas of AK ≤250 cm2 during an eight-week initial assessment period and extended 12-month follow-up. This Phase III, randomized, double-blind, vehicle-controlled trial (NCT02361216) enrolled adult patients with 5-20 AK lesions on the face/scalp (25-250cm2) or chest (∼250cm2). Patients received once-daily IngMeb or vehicle for three consecutive days on the full face, full balding scalp or ∼250cm2 on the chest. Primary endpoint: complete AK clearance (AKCLEAR 100; Week 8). Additional endpoints included: partial AK clearance (AKCLEAR 75), recurrence, patient satisfaction, cosmetic outcome and safety. IngMeb was superior to vehicle for AKCLEAR 100 (21.4% vs. 3.4%; p<0.001) and AKCLEAR 75 (59.4% vs. 8.9%; p<0.001) at Week 8. Probability of sustained clearance during 12-month follow-up was 22.9% for IngMeb-treated patients. Increased treatment-satisfaction and cosmetic outcomes were observed with IngMeb vs. vehicle. No unexpected safety signals were identified. Localized skin responses hindered maintenance of double-blinding. IngMeb 0.027% was superior to vehicle for treatment of AK areas ≤250 cm2. The safety profile of IngMeb was as expected.